← Back to Clinical Trials
Recruiting NCT06541002

NCT06541002 A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06541002
Status Recruiting
Phase
Sponsor Massachusetts General Hospital
Condition Sexual Dysfunction
Study Type INTERVENTIONAL
Enrollment 300 participants
Start Date 2025-01-27
Primary Completion 2029-04-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
SHIFT Intervention GroupEnhanced Usual Care Group

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 300 participants in total. It began in 2025-01-27 with a primary completion date of 2029-04-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This research study is evaluating the efficacy of a novel self-administered digital application for improving sexual health outcomes, quality of life, and psychological distress in hematopoietic stem cell transplant survivors.

Eligibility Criteria

Inclusion Criteria: * Adult patients (\> 18 years) who underwent autologous or allogeneic HCT \> three months prior to study enrollment * Screen positive for sexual health concerns causing distress based on the National Comprehensive Network (NCCN) survivorship guidelines screening questions Exclusion Criteria: * Patients who do not comprehend English or Spanish since SHIFT will only be available in these two languages for this efficacy trial. * Patients with any major uncontrolled psychiatric disorder or other comorbid cognitive conditions, which the treating HCT clinician believes would prohibit the patients' capacity to provide informed consent and participate in study procedures. * Patients with relapsed disease requiring treatment.

Contact & Investigator

Central Contact

Areej El-Jawahri, MD

✉ ael-jawahri@mgb.org

📞 617-724-4000

Frequently Asked Questions

Who can join the NCT06541002 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Sexual Dysfunction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06541002 currently recruiting?

Yes, NCT06541002 is actively recruiting participants. Contact the research team at ael-jawahri@mgb.org for enrollment information.

Where is the NCT06541002 trial being conducted?

This trial is being conducted at Coral Gables, United States, Boston, United States, Philadelphia, United States.

Who is sponsoring the NCT06541002 clinical trial?

NCT06541002 is sponsored by Massachusetts General Hospital. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology